摘要
目的:评价阿托伐他汀联合依折麦布(联合组)与双倍剂量阿托伐他汀(他汀组)对冠心病患者的血脂调节效果。方法:检索中国知网(CNKI)及PubMed,收集2010—2020年发表的两组治疗冠心病患者的随机对照试验,对纳入文献采用RevMan 5.3软件进行meta分析。结果:共纳入11项研究,合计2418例患者。meta分析显示,与他汀组相比,联合组显著降低血浆低密度脂蛋白胆固醇(LDL-C)水平和胆固醇(TC)水平,显著升高高密度脂蛋白胆固醇(HDL-C)水平,而在降低甘油三酯(TG)水平方面差异没有统计学意义。结论:对于冠心病患者,联合组在降低LDL-C和TC、升高HDL-C水平方面效果优于他汀组,而在TG水平的改变方面没有明显差异。
Objective:To evaluate the lipid-regulating effect of the atorvastatin combined with ezetimibe(combination group)and the double-dose atorvastatin(statin group)in patients with coronary heart disease.Methods:Randomized controlled trials(RCTs)in the two groups in the treatment of patients with coronary heart disease from 2010-2020 were retrieved and collected from CNKI and PubMed and meta-analysis was conducted using RevMan 5.3 statistical software for included literature.Results:A total of 11 RCTs were included involving 2418 patients.The results of meta-analysis showed that compared to statin group,combination group significantly decreased the levels of plasma low-density lipoprotein cholesterol(LDL-C)and total cholesterol(TC)and significantly increased the level of high-density lipoprotein cholesterol(HDL-C).There was no statistical significance in decreasing the level of triglyceride(TG).Conclusion:For patients with coronary heart disease,the combination group is more effective in decreasing the levels of LDL-C and TC and increasing the level of HDL-C than the statin group and there is no significant difference in the change of TG level.
作者
刘静
朱链链
LIU Jing;ZHU Lianlian(Department of Pharmacy,Hospital of Nankai University,Tianjin 300073,China;Department of Pharmacy,Leshan Vocational and Technical College,Sichuan Leshan 600014,China)
出处
《上海医药》
CAS
2020年第19期14-19,共6页
Shanghai Medical & Pharmaceutical Journal
